These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

63 related articles for article (PubMed ID: 23806093)

  • 1. Rationalized DNA sequencing-based protocol for genotyping patients receiving coumarin therapy.
    Rakicevic LB; Kusic-Tisma JS; Kovac MK; Backovic DT; Radojkovic DP
    Scand J Clin Lab Invest; 2013 Sep; 73(6):523-7. PubMed ID: 23806093
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Current pharmacogenetic developments in oral anticoagulation therapy: the influence of variant VKORC1 and CYP2C9 alleles.
    Oldenburg J; Bevans CG; Fregin A; Geisen C; Müller-Reible C; Watzka M
    Thromb Haemost; 2007 Sep; 98(3):570-8. PubMed ID: 17849045
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of different genetics variants: CYP2C9*2, CYP2C9*3 of cytochrome P-450 CYP2C9 and 1639G>A of the VKORC1 gene; On acenocoumarol requirement in Moroccan patients.
    Smires FZ; Habbal R; Moreau C; Assaidi A; Loriot MA; Nadifi S
    Pathol Biol (Paris); 2013 Jun; 61(3):88-92. PubMed ID: 23201087
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Allelic variants in the CYP2C9 and VKORC1 loci and interindividual variability in the anticoagulant dose effect of warfarin in Italians.
    Borgiani P; Ciccacci C; Forte V; Romano S; Federici G; Novelli G
    Pharmacogenomics; 2007 Nov; 8(11):1545-50. PubMed ID: 18034619
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cross-Validation of High-Resolution Melting Analysis-Based Genotyping Platform.
    Langaee T; Stauffer L; Galloway C; Solayman MH; Cavallari L
    Genet Test Mol Biomarkers; 2017 Apr; 21(4):259-264. PubMed ID: 28384046
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [CYP2C9 and VKORC1 gene polymorphism and acenocoumarol anticoagulant activity in Russian patients at high risk of thromboembolic complications].
    Sychev DA; Ignat'ev IV; Kropacheva ES; Emel'ianov NV; Milovanova VV; Naumova IuA; Kosovskaia AV; Dobrovol'skiĭ OB; Tashenova AI; Panchenko EP; Kukes VG
    Vestn Ross Akad Med Nauk; 2011; (3):7-10. PubMed ID: 21544933
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Impact of CYP2C9 and VKORC1 polymorphism on warfarin response during initiation of therapy].
    Liu Y; Zhong SL; Tan HH; Yang M; Fei HW; Yu XY; Lin SG
    Zhonghua Xin Xue Guan Bing Za Zhi; 2011 Oct; 39(10):929-35. PubMed ID: 22321278
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Validation of a rapid and inexpensive allele-specific amplification (ASA)-PCR genotyping assay for vitamin K antagonist pharmacogenomics.
    Spohn G; Geisen C; Luxembourg B; Sittinger K; Seifried E; Bönig H
    Mol Diagn Ther; 2011 Feb; 15(1):13-9. PubMed ID: 21469766
    [TBL] [Abstract][Full Text] [Related]  

  • 9. First report of warfarin dose requirements in patients possessing the CYP2C9*12 allele.
    O'Brien TJ; Kidd RS; Richard CA; Ha NH; Witcher P; Tran LV; Barbour A; Tuck M; McIntosh SD; Douglas JN; Harralson AF
    Clin Chim Acta; 2013 Sep; 424():73-5. PubMed ID: 23688605
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SYBR Green-based real-time PCR assay for detection of VKORC1 and CYP2C9 polymorphisms that modulate warfarin dose requirement.
    Huang SW; Li Q; Zhu SY; Li L; Xiong F; Jia YK; Xu XM
    Clin Chem Lab Med; 2009; 47(1):26-31. PubMed ID: 19117406
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevalence of CYP2C9 and VKORC1 alleles in the Argentine population and implications for prescribing dosages of anticoagulants.
    Scibona P; Redal MA; Garfi LG; Arbelbide J; Argibay PF; Belloso WH
    Genet Mol Res; 2012 Jan; 11(1):70-6. PubMed ID: 22290467
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Performance of commercial platforms for rapid genotyping of polymorphisms affecting warfarin dose.
    King CR; Porche-Sorbet RM; Gage BF; Ridker PM; Renaud Y; Phillips MS; Eby C
    Am J Clin Pathol; 2008 Jun; 129(6):876-83. PubMed ID: 18480003
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The COAG and EU-PACT trials: what is the clinical benefit of pharmacogenetic-guided coumarin dosing during therapy initiation?
    Baranova EV; Asselbergs FW; de Boer A; Maitland-van der Zee AH
    Curr Mol Med; 2014; 14(7):841-8. PubMed ID: 25109798
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacogenetics-based coumarin therapy.
    Gage BF
    Hematology Am Soc Hematol Educ Program; 2006; ():467-73. PubMed ID: 17124101
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Integrated amplification microarray system in a lateral flow cell for warfarin genotyping from saliva.
    Sebastian T; Cooney CG; Parker J; Qu P; Perov A; Golova JB; Pozza L; Iwasiow RM; Holmberg R
    Clin Chim Acta; 2014 Feb; 429():198-205. PubMed ID: 24360850
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mechanical heart valve recipients: anticoagulation in patients with genetic variations of phenprocoumon metabolism.
    Brehm K; Schack J; Heilmann C; Blanke P; Geissler HJ; Beyersdorf F
    Eur J Cardiothorac Surg; 2013 Aug; 44(2):309-14; discussion 314-5. PubMed ID: 23423913
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The bleeding risk during warfarin therapy is associated with the number of variant alleles of CYP2C9 and VKORC1 genes.
    Tomek A; Maťoška V; Kolářová T; Neumann J; Srámek M; Sarbochová I; Táborský L; Bojar M; Goetz P; Serebruany VL
    Cardiology; 2013; 125(3):182-91. PubMed ID: 23774101
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Association between CYP2C9 and VKORC1 genetic polymorphism and warfarin dose requirements].
    Yang J; Miao LY; Huang CR; Shen ZY; Jiang WP
    Zhonghua Xin Xue Guan Bing Za Zhi; 2008 Feb; 36(2):137-40. PubMed ID: 19099951
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Frequency of VKORC1 (C1173T) and CYP2C9 genetic polymorphisms in Egyptians and their influence on warfarin maintenance dose: proposal for a new dosing regimen.
    El Din MS; Amin DG; Ragab SB; Ashour EE; Mohamed MH; Mohamed AM
    Int J Lab Hematol; 2012 Oct; 34(5):517-24. PubMed ID: 22533669
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Variability of warfarin dose response associated with CYP2C9 and VKORC1 gene polymorphisms in Chinese patients.
    Ye C; Jin H; Zhang R; Sun Y; Wang Z; Sun W; Sun W; Peng Q; Liu R; Huang Y
    J Int Med Res; 2014 Feb; 42(1):67-76. PubMed ID: 24287930
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.